TransMedics Group, Inc. NGM · TMDX
Price alert —
Sign in to get a one-time email the moment TMDX crosses your price. Free accounts included.
Sign in / create a free accountTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
TMDX last traded at $73.98, down 2.7% on the day; that's in the lower part of its 52-week range ($60.10–$151.00). Right now it's trading close to its recent average, with no strong stretch in either direction.
The next scheduled earnings report (2026-07-30) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
below KC1 upper, +0.23 ATR from EMA21 — no notable pattern
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · RSI rolling over (51)
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
TMDX is a $2.6 billion company, priced at 17× last year's earnings, and it moves harder than the market (beta 1.9).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-05
- EPS (act / est)
- 0.30 / 0.61
- Surprise
- -50.9%
- Next report
- 2026-07-30
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate n…